# Development of an Optimized Adjuvanted TB Vaccine

> **NIH NIH N01** · UNIVERSITY OF MONTANA · 2024 · $358,674

## Abstract

To identify the optimal adjuvant for recombinant vaccines and inactivated flu vaccines, and to identify correlates of protection against infection or disease, experimental vaccines will be formulated with a panel of different vaccine adjuvants and tested side-by-side for immunogenicity and efficacy.

## Key facts

- **NIH application ID:** 11196784
- **Project number:** 75N93019C00045-P00023-9999-4
- **Recipient organization:** UNIVERSITY OF MONTANA
- **Principal Investigator:** JAY EVANS
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $358,674
- **Award type:** —
- **Project period:** 2021-09-30 → 2025-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11196784

## Citation

> US National Institutes of Health, RePORTER application 11196784, Development of an Optimized Adjuvanted TB Vaccine (75N93019C00045-P00023-9999-4). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/11196784. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*